

VU Research Portal

Pediatric acute lymphoblastic leukemia: Quality of life and cost-effectiveness of treatment

van Litsenburg, R.R.L.

2012

document version

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

citation for published version (APA)

van Litsenburg, R. R. L. (2012). *Pediatric acute lymphoblastic leukemia: Quality of life and cost-effectiveness of treatment*.

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:

vuresearchportal.ub@vu.nl

Chapter 8

Health-related quality of life and utility scores in short-term survivors of pediatric acute lymphoblastic leukemia

Raphaële R.L. van Litsenburg, Jaap Huisman, Hein Raat,
Gertjan J.L. Kaspers, Reinoud J.B.J. Gemke

Submitted

Abstract

Purpose: Increase of survival in pediatric acute lymphoblastic leukemia (ALL) has made outcomes such as health related quality of life (HRQL) and economic burden more important. To make informed decisions on the use of healthcare resources, costs as well as utilities need to be taken into account. Among the preference-based HRQL instruments, the Health Utilities Index (HUI) is the most employed in pediatric cancer. Information on utility scores during ALL treatment and in long term survivors is available, but utility scores in short-term survivors are lacking. This study assesses utility scores, health state and HRQL in short-term (6 months-4 years) ALL survivors.

Methods: Cross-sectional single centre cohort study of short-term ALL survivors using HUI3 proxy assessments.

Results: Thirty-three survivors (median 1.5 years off treatment) reported 14 unique health states. The majority of survivors (61%) enjoyed a perfect health, but 21% had three affected attributes. Overall HRQL was non-significantly lower compared to the norm, although the difference was large and may be clinically relevant. Cognition was significantly impaired ($p=0.03$).

Conclusion: Although 61% of short-term survivors of ALL report no impairment, the health status of the other patients lead to a clinically important impaired HRQL compared to norms. Prospective studies assessing utility scores associated with pediatric ALL should be performed, enabling valid and reliable cost-utility analyses for policy makers to make informed decisions.

Introduction

Acute Lymphoblastic Leukemia (ALL) is the most common type of childhood cancer. Over the past decades survival improved substantially, and is now 80-85% [2, 63]. In addition to survival and morbidity, health-related quality of life (HRQL) and cost-effectiveness of interventions are increasingly recognized as important outcome measures. In order to make informed decisions on the use of healthcare resources, the costs of interventions as well as the associated utilities need to be taken into account. Utility scores are derived from preference-based HRQL measures and can be used for the calculation of quality-adjusted life-years (QALY). QALY are valuable in economic evaluations because they incorporate the gained life-years as well as the quality of the life-years, and thus allow for more deliberated decision making.

Among the available preference-based HRQL instruments in pediatric oncology, the Health Utilities Index (HUI) is frequently employed [158]. Most studies that have used the HUI in pediatric ALL involved either long-term survivors (>4 years) [119, 163, 166] or children on active treatment [106, 170, 175]. Information on utility scores and HRQL measured with the HUI in the years in between (i.e. in short-term survivors) is, however, still lacking but is essential to perform robust cost-utility analysis.

The aim of the present study was twofold: 1) to present utility scores and 2) to assess health state and HRQL, in short-term survivors of pediatric ALL.

Methods

Patients

A single-centre cohort of parents of ALL survivors (≥ 5 years of age) was invited to participate in a cross-sectional HRQL assessment. Survivors were six months to four years after the end of treatment with no signs of recurrence. Parents were required to be fluent in Dutch. A sample size of 27 was necessary to detect significant differences between ALL patients and norms [119] with 80% power and an effect size of 0.80 at a 5% significance level (two sided test). The study, involving the participation of healthy adults as proxy-respondents, was waived submission for full consideration by the review board of our institution. All participating parents gave their informed consent.

Instrument

The 15-question parent-proxy format of the Health Utilities Index Mark 3 (HUI3) was used [158]. It consists of eight attributes (vision, hearing, speech, ambulation, dexterity, cognition, pain), which can be described in 5 or 6 levels. Level 1 represents no impairment, higher levels represent more severe impairment. Attribute levels are used to

determine single attribute utility (SAU) scores and multi attribute utility (MAU) scores using published utility functions. Attribute scores of 0.00 represent being dead and 1.00 living in perfect health. Differences in means greater than 0.03 for MAU scores and greater than 0.05 for SAU scores can be considered clinically important [158]. Charts were reviewed for those children that did not participate, in order to identify impaired health states. HRQL was compared to Dutch parent-proxy norms [176, 177].

The HUI was distributed during an outpatient clinic visit or sent to the patient's home address with a stamped return envelope. A second questionnaire was sent to the patient's home address if it was not returned after 2 to 4 weeks. If the second questionnaire was not returned either, the family was regarded as not interested in participating.

Statistical analysis

The Statistical Package for Social Sciences (SPSS) for Macintosh version 18.0 was used for data analyses. The differences in descriptive variables between participants and non-participants were calculated using Fisher's exact test and Mann-Whitney U tests. Mann-Whitney U tests were used to assess the difference in scores between ALL patients and the norm. The effect of time since diagnosis, age at diagnosis and age at survey on HRQL was assessed using Pearson's correlation. Significance level was set at $p < .05$ (2-sided) for all analyses.

Results

Demographic variables

Thirty-three parents of ALL patients participated, Figure 8.1. There were no missing items on the questionnaires. Median time off treatment was 1.5 years (range 0.5-3.9). None of the children were irradiated or received a stem cell transplantation. There were




Figure 8.1 Study participation

no differences in age or gender between the participants and the non-participants, Table 8.1. Chart review of the non-participants did not reveal any health state impairments.

Table 8.1 Demographic variables of the ALL patients

	Participants	Non-participants	p
N ^a	33	18	-
Boys (%)	66%	53%	0.39
Age at diagnosis (years, mean±SD)	5.5 ± 3.2	5.5 ± 3.5	0.95
Age at study (years, mean±SD)	9.3 ± 3.3	NA	-
Median years since end off treatment (range)	1.5 (0.5-3.9)	NA	-

^a One questionnaire was returned without identification. The demographic variables of this unknown patient were therefore analyzed in the non-participant group. NA=not applicable.

Health-related quality of life

A total of 14 unique health states were found, Table 8.2. The majority of children (n=20, 61%) enjoyed a perfect health state. Impairments on three or more attributes were reported for seven (21%) children. Over 90% of participants had no impairment on the attributes vision, ambulation, hearing and dexterity, Table 8.3. Impairment was most often reported for cognition, and it was the only attribute on which level four (“somewhat forgetful, and have a little difficulty when trying to think or solve day-to-day problems”) occurred (n=3, 9%).

Table 8.2 Frequency distribution of unique HUI3 health state vectors in the ALL population

Attribute	Number of affected attributes													
	0	1	1	1	2	2	2	3	3	3	3	3	3	4
Vision	1	2	1	1	2	1	1	1	1	2	1	1	1	1
Hearing	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Speech	1	1	1	1	1	2	1	1	1	1	3	3	3	2
Ambulation	1	1	1	1	1	1	1	3	1	1	1	1	1	1
Dexterity	1	1	1	1	1	1	1	2	2	1	1	1	1	1
Emotion	1	1	1	2	2	1	1	1	1	1	1	2	1	2
Cognition	1	1	2	1	1	2	2	1	3	3	2	4	4	4
Pain	1	1	1	1	1	1	3	2	2	2	2	1	2	2
Total patients (N, %)	20 (61%)	1 (3%)	1 (3%)	1 (3%)	1 (3%)	1 (3%)	1 (3%)	1 (3%)	1 (3%)	1 (3%)	1 (3%)	1 (3%)	1 (3%)	1 (3%)

More affected attributes indicate more impairments. Maximal possible number of affected attributes is eight.

The mean MAU of the ALL patients was 0.83 compared to 0.93 in healthy children, but the difference was not statistically significant (p=0.61), Table 8.4. Children with ALL had a significantly lower HRQL on the dexterity and cognition attribute (p<0.001 and

Table 8.3 Frequency distribution of HUI3 attribute levels in the ALL population

Attribute	Levels (N,%)					
	1	2	3	4	5	6
Vision	30 (91%)	3 (9%)	0	0	0	0
Hearing	33 (100%)	0	0	0	0	0
Speech	28 (85%)	2 (6%)	3 (9%)	0	0	NA
Ambulation	32 (97%)	0	1 (3%)	0	0	0
Dexterity	31 (94%)	1 (3%)	1 (3%)	0	0	0
Emotion	29 (88%)	4 (12%)	0	0	0	NA
Cognition	24 (73%)	4 (12%)	2 (6%)	3 (9%)	0	0
Pain	26 (79%)	6 (18%)	1 (3%)	0	0	NA

NA = not applicable. Level 1 indicates no impairment; level 5 or 6 indicates the most severe impairment.

Table 8.4 HUI3 Utility scores of the ALL patients compared to the reference population (mean±SD)

Attribute	ALL	Reference population ^a	Difference ^b	p-value
Vision	0.996 ± 0.015	0.998 ± 0.015	0.002	0.59
Hearing	1.000 ± 0.000	0.999 ± 0.014	0.001	0.46
Speech	0.959 ± 0.103	0.991 ± 0.027	0.032	0.41
Ambulation	0.990 ± 0.057	0.999 ± 0.015	0.009	0.15
Dexterity	0.993 ± 0.029	0.999 ± 0.010	0.006	<0.001
Emotion	0.989 ± 0.030	0.988 ± 0.037	-0.001	0.49
Cognition	0.951 ± 0.094	0.983 ± 0.052	0.032	0.03
Pain	0.979 ± 0.049	0.989 ± 0.034	0.010	0.49
Multi Attribute Score	0.830 ± 0.266	0.929 ± 0.124	0.099	0.61

Higher scores indicate a better health-related quality of life. ^a The reference population consists of parent-proxy scores of 1435 children aged 4-13 years [176, 177]. ^b The difference in mean scores between ALL patients and the reference population. Negative differences indicate higher scores in the ALL population. Differences greater than 0.05 can be considered clinically relevant for the single attribute score and difference greater than 0.03 for the multi attribute score.

p=0.03, respectively). There were no significant differences on the other attributes. There was a negative association between time off treatment and scores on the vision attribute ($r=-0.49$, $p=0.004$). Time off treatment was not related to the other attributes, nor was age at diagnosis and age at survey.

Discussion

The primary aim of this study was to provide utility scores for short-term survivors of ALL for future reference in economic evaluations. Economic evaluations of pediatric (oncology) interventions are emerging [153-155], and will probably prove even more necessary in the future as expensive and time-consuming health-care technology

evolves. Information on utilities can be essential in determining which alternative is most cost-effective. This study adds to the limited available information on utility scores in pediatric ALL. Previous ALL parent-proxy MAU scores were 0.83-0.89 in children on active treatment [106] and 0.86-0.93 in long(er)-term survivors [119, 164], compared to 0.83 in our study. The MAU scores for children on active treatment were derived from the HUI2. Even though some studies have found HUI2 scores to be 0.01-0.05 points higher compared to HUI3 scores [164, 165], the results of this study suggest that HRQL in short-term survivors (MAU 0.83) did not improve much from HRQL in children on active treatment. Meeske et al. also reported a low parent-proxy rated HRQL in short term survivors of ALL [82]. Low parent-rated HRQL can be explained by increased distress and fear of recurrence after the completion of their child's cancer treatment [23]. Problems in parental psychosocial functioning such as depression, worries and psychosocial distress have all been associated with a lower perception of HRQL [74, 91, 120].

The secondary aim of this study was to assess the health state and HRQL of short-term ALL survivors. The results demonstrate that impairments on three or more attributes occurred in 21% of patients, but that 61% of survivors did not report any impairment and were considered to have a perfect health. Overall HRQL was non-significantly lower compared to the norm, although the difference may be clinically relevant since the difference in scores between both groups was larger than what is considered clinically important [158]. Cognition was the most seriously and statistically significantly affected attribute. Cognitive defects have been reported after pediatric ALL treatment with chemotherapy only, as was summarized in a review of twenty-one studies by Buizer et al [12]. A statistically significantly lower HRQL in ALL patients was also found on the dexterity attribute, but with only a small difference in scores compared to the norm. This has not been described before in ALL survivors [119, 156, 163, 165] and may not be clinically relevant. Interestingly, previous research in survivors reported an impaired emotional HRQL [26, 119, 165], and it is unclear why such differences were not found in this study. Further, a significant association between impaired vision and time off treatment was found. An increased risk of cataract has been described in childhood cancer survivors treated with glucocorticosteroids [178]. This could have contributed to the association found in this study, although no information on the cause of the impaired vision in this cohort was available.

Several limitations of this study have to be mentioned. It is a cross-sectional, single centre study with a relatively small number of patients. Further, parental reports were used because most children were too young for the use of HUI3 self reports. Children and parents do not always agree on their perception of HRQL and differences have been found for the HUI3 as well [36, 156, 163]. Elevated levels of psychological distress in parents [101] and adaptation to the disease process in patients [38] can both affect

HRQL assessment. It would therefore seem preferable to collect both patient and proxy assessments of HRQL in the future, although in pediatric oncology the patients are often too young or too ill.

In conclusion, information on utility scores associated with pediatric ALL is scarce but vital for policy makers make informed decisions based on valid and reliable cost-utility analyses. This study suggests clinically relevant decreased overall HRQL in short-term survivors of childhood ALL although the difference was not statistically significant. Rigorous longitudinal studies to assess utility scores during and after treatment for pediatric ALL are necessary.